As scientists home in on new therapeutic approaches for Duchenne muscular dystrophy, researchers have harnessed a novel protein measuring technology to uncover blood-based protein biomarkers for the disease, potentially accelerating diagnostic and drug development.
Gilead Sciences has a new swath of research showing that investing in new hep C therapies could potentially save the U.S. and Europe billions of dollars in lost productivity.
Irish researchers have developed a gel containing clusters of pancreatic cells that they say can control glucose levels for up to 5 years when administered via a minimally invasive injection procedure being developed by medical device bigwig Boston Scientific.
Trialbee has raised $5 million to expand its clinical trial recruitment business in the U.S.
Royal Philips and the Academic Medical Center in Amsterdam, the Netherlands, will collaborate in a European multicenter trial of a new diagnostic technique to assess the results of minimally invasive treatment for diabetic foot and critical limb ischemia. The trial is slated to start this summer with final results expected in 2017.
There is no cure for genital herpes, but Genocea is getting closer to marketing an immunotherapy that could control herpes symptoms. The Massachusetts-based company announced Wednesday that it met its goals in a Phase II study of its investigational GEN-003 vaccine.
After a troublesome flu vaccine season, the NIH has announced that it'll lend a hand to Vanderbilt University as researchers there attempt to develop an improved, "universal" vaccine against the virus.
With ambitious plans for the next year, Ahmedabad-based Zydus Cadila's coming launches could alter the vaccines landscape in India and challenge established players there.
BioNTech has snagged a small upfront fee to enter into an immuno-oncology co-development pact with Genmab. The deal was unveiled one week after Eli Lilly invested $30 million (€27 million) in BioNTech as part of an immuno-oncology deal worth a potential $300 million per asset.
Ablynx has entered into a collaboration with Sanofi's Genzyme to investigate the use of its single-domain antibodies against a target involved with multiple sclerosis. The deal gives Genzyme the exclusive right to test the antibodies in models relevant to multiple sclerosis.